1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 11 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2014A pilot study to assess the impact of patient, genetic and disease factors on response to the disease modifying anti-rheumatic drug leflunomideWiese, M.; Hopkins, A.; Spargo, L.; McWilliams, L.; O'Doherty, C.; Cleland, L.; Proudman, S.; Australian Rheumatology Association 55th Annual Scientific Meeting (17 May 2014 - 20 May 2014 : Hobart, Tasmania)
2013Variability in genes that encode N-acetyl transferase 2 and ABCG2 and disease outcomes in early rheumatoid arthritisWiese, M.; Alotabi, N.; O'Doherty, C.; Sorich, M.; Suppiah, V.; Cleland, L.; Proudman, S.; Australian Rheumatology Association 54th Annual Scientific Meeting (18 May 2013 - 22 May 2013 : Perth, W.A.)
2016Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?Wabe, N.; Sorich, M.; Wechalekar, M.; Cleland, L.; McWilliams, L.; Lee, A.; Hall, C.; Spargo, L.; Metcalf, R.; Proudman, S.; Wiese, M.
2017Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritisWabe, N.; Sorich, M.; Wechalekar, M.; Cleland, L.; Mcwilliams, L.; Lee, A.; Spargo, L.; Metcalf, R.; Hall, C.; Proudman, S.; Wiese, M.
2015Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three yearsWabe, N.; Sorich, M.; Wechalekar, M.; Cleland, L.; McWilliams, L.; Lee, A.; Spargo, L.; Metcalf, R.; Hall, C.; Proudman, S.; Wiese, M.
2015The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies - a systematic reviewMohamed, H.; Sorich, M.; Kowalski, S.; McKinnon, R.; Proudman, S.; Cleland, L.; Wiese, M.
2011Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MSRakhila, H.; Rozek, T.; Hopkins, A.; Proudman, S.; Cleland, L.; James, M.; Wiese, M.
2012Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritisWiese, M.; Schnabl, M.; O'Doherty, C.; Spargo, L.; Sorich, M.; Cleland, L.; Proudman, S.
2012Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritisO'Doherty, C.; Schnabl, M.; Spargo, L.; Cleland, L.; James, M.; Proudman, S.; Wiese, M.
2016Effect of adherence to protocolized targeted intensifications of disease-modifying antirheumatic drugs on treatment outcomes in rheumatoid arthritis: results from an Australian early arthritis cohortWabe, N.; Sorich, M.; Wechalekar, M.; Cleland, L.; McWilliams, L.; Lee, A.; Spargo, L.; Metcalf, R.; Hall, C.; Proudman, S.; Wiese, M.

Discover